Prevents pregnancy. ANDA 207081, held by Aurobindo Pharma. Desogestrel; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 207081 (Kalliga), held by Aurobindo Pharma, was first approved by FDA on May 17, 2017, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cyred EQ tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the Norplant System depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates. In a clinical trial with Cyred EQ, 1,195 subjects completed 11,656 cycles and a total of 10 pregnancies were reported.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 17, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Kalliga0.15MG;0.03MG · tablet;oral-28 | Desogestrel; Ethinyl Estradiol | Rx |
| Apr 29, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 28, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 17, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters